CTOs on the Move

GenCanna

www.gencanna.com

 
Founded by industry pioneers who championed the world`s leading hemp CBD genetics, formulations and spearheaded groundbreaking US hemp legislation, GenCanna ™ is focused on scaling our premium hemp genetics production for food products with easy availability locally, nationally and globally.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

GenCanna raised $30M on 11/12/2018

Similar Companies

Agrivida

Agrivida is developing and commercializing solutions that are the next evolutionary step in animal nutrition, using the plant as a factory to produce and deliver highly differentiated products. We are transforming the economics of enzyme and animal feed production through our use of plant-expressed enzymes and plant modification to develop transformational products for monogastric and ruminant animal nutrition.

Valitor

Valitor, Inc. has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacokinetics, target specificity and bioactivity. Our technology platform can be broadly applied to improve the pharmacological properties of many protein drugs that are currently approved or under development. We currently have development pipelines in the fields of dermatology, ophthalmology, orthopedics, and stem cell therapy that highlight the capabilities of our novel drug products.

Supernus Pharmaceuticals

Supernus Pharmaceuticals is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Appleton Area Health Services

Appleton Area Health Services is a Appleton, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Batu Biologics

Batu Biologics is a biotechnology-based pharmaceutical company focused on the development and commercialization of novel therapies that target the “Achilles Heel of Cancer:” the tumor blood vessels. Batu’s flagship therapeutic, ValloVax™, is an angiogenesis targeting cancer vaccine in the late stages of preclinical development. Batu Biologics plans to file an Investigational New Drug (IND) application for ValloVax in Q1 of 2015, seeking clinical approval to treat patients with lung cancer.